Neuronetics, Inc. filings document the public reporting record for a Nasdaq-listed medical technology and healthcare company with common stock traded under STIM. Recent Form 8-K reports furnish operating results, investor presentation materials, executive appointments and retirements, compensation arrangements, restructuring charges, and material agreements tied to credit facilities and registration rights.
The company’s proxy materials describe annual meeting voting matters, director elections, auditor ratification, advisory executive compensation votes, and equity incentive plan approvals. Together with event reports, the filings disclose governance procedures, capital-structure matters, Nasdaq-listed security information, and contractual obligations associated with Neuronetics’ medical device and clinic-services operations.
Neuronetics, Inc. ten percent owner Jorey Chernett reported an open-market purchase of 385,442 shares of common stock at a weighted average price of $1.25 per share. After this transaction, Chernett directly beneficially owned 9,778,988 shares of Neuronetics common stock.
The shares were acquired in multiple trades at prices ranging from $1.23 to $1.26 per share, calculated on a weighted average basis. The filing also corrects a prior clerical error, noting that the previously reported beneficial ownership had been understated by 270 shares.
Neuronetics, Inc. major shareholder Jorey Chernett reported an open-market purchase of 500,000 shares of Common Stock at a weighted average price of $1.35 per share. The shares were bought in multiple trades between $1.28 and $1.41. Following this transaction, Chernett directly holds 9,393,276 shares.
Neuronetics, Inc. 10% owner Jorey Chernett reported open-market purchases of a total of 150,000 shares of common stock. The buys occurred on March 25 and March 26 at reported prices of $1.40 and $1.44 per share, respectively. After these transactions, Chernett directly owns 8,893,276 Neuronetics shares. A footnote explains that one purchase reflects a weighted-average price for multiple trades executed between $1.38 and $1.42 per share.
Neuronetics EVP, CFO and Treasurer Steven Pfanstiel reported an open-market sale of 16,431 shares of common stock at a weighted average price of $1.34 per share. According to the footnotes, these were non-discretionary sales made solely to satisfy tax withholding obligations upon vesting of a performance restricted stock unit award. After the transaction, Pfanstiel directly holds 828,781 shares of Neuronetics common stock, indicating this was a relatively small, tax-driven adjustment to his overall position rather than a discretionary portfolio move.
Former officer and director Keith J. Sullivan of Neuronetics, Inc. reported an open-market coded sale of 46,289 shares of common stock at a weighted average price of $1.34 per share. According to the footnotes, these were non-discretionary sales made solely to satisfy his tax withholding obligation upon vesting of a performance restricted stock unit award.
The shares were sold in multiple trades at prices ranging from $1.48 to $1.20 per share. After these transactions, Sullivan directly holds 1,590,924 shares of Neuronetics common stock, indicating he retained a substantial equity position following the tax-related disposition.
Neuronetics, Inc. executive William Andrew Macan reported an open-market sale of 16,005 shares of common stock at a weighted average price of $1.34 per share. According to the disclosure, these were non-discretionary sales made solely to cover tax withholding upon vesting of a performance restricted stock unit award, and he continues to hold 897,270 shares directly.
REUVERS DANIEL L. reported acquisition or exercise transactions in this Form 4 filing.
Neuronetics, Inc. President and CEO Daniel L. Reuvers reported an equity compensation award of 1,500,000 shares of common stock on March 23, 2026, coded as a grant. The award is structured as restricted stock units that vest in three equal annual installments beginning on March 23, 2027, subject to his continuous service. Each RSU gives a contingent right to receive one share of common stock, and following this award he reports 1,500,000 shares/units held directly.
Neuronetics, Inc. filed an initial insider ownership report for President and CEO Daniel L. Reuvers. This Form 3 identifies him as an executive officer but does not show any stock transactions or option exercises. It serves as a baseline disclosure of his status as a reporting insider under SEC rules.
Neuronetics, Inc. insider activity: 10% owner Jorey Chernett purchased 169,472 shares of Neuronetics common stock in an open-market transaction at a weighted average price of $1.41 per share. The footnote states the trades occurred in multiple transactions between $1.36 and $1.44 per share, rounded to the nearest cent.
Following this purchase, Chernett directly holds 8,743,276 Neuronetics shares. The filing notes he can provide detailed breakdowns of the number of shares bought at each specific price upon request by the company, its security holders, or the SEC staff.
Neuronetics, Inc. 10% owner Jorey Chernett reported significant open-market buying of the company’s common stock. On March 18, 2026, he purchased 607,400 shares at a weighted average price of $1.35 per share in multiple trades. On March 19, 2026, he bought an additional 450,000 shares at a weighted average price of $1.33 per share, also across multiple transactions. Following these purchases, Chernett directly owns 8,573,804 shares of Neuronetics common stock.